Content about Sanofi

May 1, 2013

Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.

PARSIPPANY, N.J. — Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said Wednesday.

Actavis Specialty Brands' acquisition of Valeant's metronidazole vaginal gel is in the 1.3% strength. The deal includes an upfront payment, milestone payments and royalties for the first three years after the drug is commercialized. Actavis hopes to market the drug as early as the middle of next year.

April 11, 2013

Chattem announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

BRIDGEWATER, N.J. — Chattem on Thursday announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

"We identified an opportunity in the topical anti-itch category and leveraged our experience with Allegra Allergy to introduce a new product for common skin irritations that not only helps stop the itch but also provides a moisturizing benefit," stated John Stroud, EVP marketing, Chattem. 

April 10, 2013

Chattem introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator.

CHATTANOOGA, Tenn. — Chattem on Tuesday introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator. 

"The innovative packaging is the first of its kind for poison ivy relief," stated Liz Roques, assistant brand manager at Chattem. "The individual Snapplicators include a single treatment so consumers don't have to touch the affected area."

April 4, 2013

Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said.

ZUG, Switzerland — Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said Thursday.

March 22, 2013

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

CAMBRIDGE, Mass. — Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

Genzyme, a division of French drug maker Sanofi, announced results of an extension study of the drug Lemtrada (alemtuzumab). The study was a follow-up to two other late-stage clinical studies of the drug, finding that relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug.

March 4, 2013

The Centers for Disease Control and Prevention set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal.

NEW YORK — The Centers for Disease Control and Prevention last week set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal

Quadrivalent vaccines will contain two A strains and two B strains of flu. The triumvirate vaccines in use today contain two A strains and one B strain of flu. 

February 25, 2013

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

February 19, 2013

Sergeant's Pet Care Products has launched a generic version of a commonly used spray for killing fleas and ticks in dogs and cats, the company said Tuesday.

OMAHA, Neb. — Sergeant's Pet Care Products has launched a generic version of a commonly used spray for killing fleas and ticks in dogs and cats, the company said Tuesday.

Sergeant's announced the launch of Pronyl, a version of Sanofi's Frontline. Pronyl uses the same active ingredient, Fipronil, but also uses what the company calls Bag-on-Valve technology that allows a continuous and quiet spray from any angle.

February 12, 2013

The Colon Cancer Challenge Foundation, a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, presented Sanofi with its annual Blue Star Corporate Award.

NEW YORK — Sanofi US was named corporate partner of the year by the Colon Cancer Challenge Foundation (CCCF), a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, and presented with CCCF's annual Blue Star Corporate Award.

February 11, 2013

Sun & Skin Care Research announced that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

COCOA, Fla. — Sun & Skin Care Research announced on Monday that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately

February 8, 2013

During a quarterly conference call Thursday, Sanofi president global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

PARIS — During a quarterly conference call Thursday, Sanofi president of global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

"We plan to relaunch the product, which has been absent of the American markets for production problems on the side of J&J," he told analysts. "We intend to launch the product by the end of 2013, which will further accelerate the performance of Chattem in the United States."

January 29, 2013

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

BRIDGEWATER, N.J. — Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

 

January 28, 2013

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

CAMBRIDGE, Mass. — The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

Genzyme, a division of French drug maker Sanofi, said the FDA accepted its application seeking approval for Lemtrada (alemtuzumab) for relapsing MS. The company expects the agency to decide whether to approve the drug in the second half of this year.

January 10, 2013

The Food and Drug Administration is ordering the makers of several sleep drugs to lower the dosage due to the risk that they can impair patients the morning after, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration is ordering the makers of several sleep drugs to lower the recommended dosage due to the risk that they can impair patients the morning after, the agency said Thursday.

The FDA announced that it was requiring the manufacturers of drugs containing the active ingredient zolpidem to lower the current recommended dosage in light of new data showing that the morning after use, the drug can remain in the blood in sufficient quantities to impair activities that require alertness, such as driving.

January 7, 2013

Sanofi announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

PARIS — Sanofi on Monday announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

January 4, 2013

According to a Bloomberg report, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.

NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion. 

B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well. 

Other companies who have been invited to bid include Merck and Pfizer. 

January 2, 2013

Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

SAN DIEGO — Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 27, 2012

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

October 22, 2012

Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

SWIFTWATER, Pa. — Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

October 18, 2012

Sanofi Pasteur on Thursday announced it has filed for approval of a four-strain flu shot to the Food and Drug Administration.

 SWIFTWATER, Pa. — Sanofi Pasteur on Thursday announced it has filed for approval of a four-strain flu shot to the Food and Drug Administration. An action date is anticipated in the second quarter of 2013. 

October 17, 2012

Coca-Cola and Sanofi are partnering to launch a line of "beauty drinks" in France under the Oenobiol Beautific brand. The drinks claim to "help strengthen hair and nails, embellish skin, lose weight and improve vitality."

ATLANTA – Coca-Cola and Sanofi are partnering to launch a line of "beauty drinks" in France under the Oenobiol Beautific brand. The drinks claim to "help strengthen hair and nails, embellish skin, lose weight and improve vitality."

The beauty drinks will be sold in a "small scale pilot" to a limited number of pharmacies in the country, according to a statement from the Coca-Cola business unit in France. Coca-Cola declined to provide further details.